ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Assessing Immunosuppression with Immunological Testing and Surveillance Biopsies Late after Liver and Intestine Transplantation (LT, IT)

L. Remaley, R. Falik, K. Soltys, G. Bond, J. Winnier, P. Kachmar, C. Ashokkumar, A. Ganoza, A. Kepler, A. Khanna, J. Squires, P. McKiernan, J. Rudolph, F. Alissa, G. Mazariegos, R. Sindhi

Pediatric Transplant, Pittsburgh, PA

Meeting: 2020 American Transplant Congress

Abstract number: 417

Keywords: Immunosuppression, Liver transplantation, Protocol biopsy, T cells

Session Information

Session Name: Biomarkers, Immune Assessment and Clinical Outcomes IV

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: Assessing adequacy of immunosuppression is essential during late allograft surveillance after LT or IT.

*Methods: To explain why allograft function tests can be normal despite varying drug levels, and abnormal allograft biopsies (Bx), we evaluated 1) standard deviation in 3-6 consecutive tacrolimus blood levels (Tac SD), 2) donor-specific anti-HLA antibodies (DSA), 3) risk of acute cellular rejection (ACR-risk) with donor-specific CD154+T-cytotoxic memory cells (CD154+TcM), and 4) surveillance Bx after LT or IT.

*Results: 261 visits from 95 subjects, mean 2.8 (range 1-6) visits per subject were evaluated at median 1353 post-transplant days (369-7969). The minimum interval between visits was 12 weeks. Subjects included 52 males, 76 LT and 19 IT, with median age 12.4 years (range 1.4-27). Tac SD <2 was seen at each visit in 62 subjects. Tac SD =/> 2 was found at least once in 33 subjects. More subjects with Tac SD >/= 2 were medication-non-adherent 11/33 vs 9/62, p=0.0385, or experienced ACR, 18/33 vs 18/62, p=0.044, compared with the remaining subjects. Compared with 211 visits with Tac SD <2, the 50 visits with Tac SD =/> 2 were also associated with increased ACR-risk with CD154+TcM, 90/211 vs 32/50, p=0.008, and higher mean (SD) Tac levels, 5 (2.5) vs 8.3 (6.3) ng/ml, respectively, p<0.001. Among 133 biopsies from 74 subjects, 69 showed no ACR. Increased ACR-risk measured with CD154+TcM or DSA were present at 31/46 and 24/36 biopsies with ACR, respectively; at 3/12 and 8/9 biopsies that were indeterminate for ACR, and at 3 of 4 and 4/4 biopsies with fibrosis. Sensitivity and negative predictive values for ACR were 67% and 71% for the ACR-risk parameter CD154+TcM and 67% and 75% for DSA. Either increased ACR-risk or DSA were present during 36/40 (90%) ACR episodes. Together, absent DSA and decreased ACR-risk with CD154+TcM predicted absence of ACR in 83%. Backward stepwise logistic regression analysis confirmed a) association of ACR-risk measured by CD154+TcM, with SD=/>2 (p=0.007) and ACR (p=0.034), b) association of Tac SD=/>2 with Tac levels (p<0.001) and ACR-risk measured with CD154+TcM (p=0.051), and c) association of DSA with time after transplantation (p<0.001), ACR-risk measured with CD154+TcM (p=0.045) and immunologic injury on Bx (p<0.001).

*Conclusions: Highly variable Tac levels are associated with increased donor-specific T-cell alloreactivity measured with CD154+TcM, acute cellular rejection, and non-adherence. Late consequences of increased T-cell alloreactivity and unstable immunosuppression include humoral sensitization and allograft injury. Optimal immunosuppression is associated with immunologic and histologic quiescence.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Remaley L, Falik R, Soltys K, Bond G, Winnier J, Kachmar P, Ashokkumar C, Ganoza A, Kepler A, Khanna A, Squires J, McKiernan P, Rudolph J, Alissa F, Mazariegos G, Sindhi R. Assessing Immunosuppression with Immunological Testing and Surveillance Biopsies Late after Liver and Intestine Transplantation (LT, IT) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/assessing-immunosuppression-with-immunological-testing-and-surveillance-biopsies-late-after-liver-and-intestine-transplantation-lt-it/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences